These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


386 related items for PubMed ID: 25962349

  • 1. Om.breast cancer in very young women aged 25 year-old or below in the center of Tunisia and review of the literature.
    Ben Abdelkrim S, Fathallah K, Rouatbi R, Ayachi M, Hmissa S, Mokni M.
    Pathol Oncol Res; 2015 Jul; 21(3):553-61. PubMed ID: 25962349
    [Abstract] [Full Text] [Related]

  • 2. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
    Luhtala S, Staff S, Tanner M, Isola J.
    Tumour Biol; 2016 Jul; 37(7):9813-23. PubMed ID: 26810187
    [Abstract] [Full Text] [Related]

  • 3. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R.
    Cancer; 2006 Aug 15; 107(4):696-704. PubMed ID: 16826579
    [Abstract] [Full Text] [Related]

  • 4. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.
    Breast Cancer; 2015 May 15; 22(3):292-9. PubMed ID: 23749689
    [Abstract] [Full Text] [Related]

  • 5. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
    Tang D, Xu S, Zhang Q, Zhao W.
    Med Oncol; 2012 Jun 15; 29(2):526-33. PubMed ID: 21519872
    [Abstract] [Full Text] [Related]

  • 6. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
    Kos T, Aksoy S, Sendur MA, Arik Z, Civelek B, Kandemir N, Ozdemir NY, Zengin N, Altundag K.
    J BUON; 2013 Jun 15; 18(3):608-13. PubMed ID: 24065471
    [Abstract] [Full Text] [Related]

  • 7. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
    Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.
    Breast Cancer Res; 2009 Jun 15; 11(1):R11. PubMed ID: 19239686
    [Abstract] [Full Text] [Related]

  • 8. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P, Valavanis C, Gavressea T, Tzaida O, Trihia H, Lekka I.
    J BUON; 2012 Jun 15; 17(2):277-83. PubMed ID: 22740206
    [Abstract] [Full Text] [Related]

  • 9. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
    Shandiz FH, Shabahang H, Afzaljavan F, Sharifi N, Tavasoli A, Afzalaghaee M, Roshanzamir E, Pasdar A.
    Asian Pac J Cancer Prev; 2016 Jun 15; 17(3):1347-50. PubMed ID: 27039770
    [Abstract] [Full Text] [Related]

  • 10. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
    Ulas A, Kos T, Avci N, Cubukcu E, Olmez OF, Bulut N, Degirmenci M.
    Asian Pac J Cancer Prev; 2015 Jun 15; 16(4):1643-9. PubMed ID: 25743846
    [Abstract] [Full Text] [Related]

  • 11. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [Abstract] [Full Text] [Related]

  • 12. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY, Turker I, Aksoy S, Oksuzoglu B, Helvaci K, Yildirim Ozdemir N, Uyeturk U, Uysal Sonmez O, Budakoglu B, Zengin N.
    J BUON; 2013 Aug 01; 18(3):585-93. PubMed ID: 24065468
    [Abstract] [Full Text] [Related]

  • 13. Clinical and biological characteristics of breast cancer.
    Kocic B, Filipovic S, Petrovic B, Mijalkovic D, Rancic N, Poultsidi A.
    J BUON; 2010 Aug 01; 15(4):660-7. PubMed ID: 21229626
    [Abstract] [Full Text] [Related]

  • 14. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
    Raica M, Cîmpean AM, Ceausu RA, Fulga V, Nica C, Rudico L, Saptefrati L.
    Anticancer Res; 2014 Mar 01; 34(3):1435-40. PubMed ID: 24596391
    [Abstract] [Full Text] [Related]

  • 15. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.
    Ibrahim T, Farolfi A, Scarpi E, Mercatali L, Medri L, Ricci M, Nanni O, Serra L, Amadori D.
    Oncology; 2013 Mar 01; 84(3):150-7. PubMed ID: 23257904
    [Abstract] [Full Text] [Related]

  • 16. Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.
    Li CY, Zhang S, Zhang XB, Wang P, Hou GF, Zhang J.
    Asian Pac J Cancer Prev; 2013 Mar 01; 14(6):3779-84. PubMed ID: 23886182
    [Abstract] [Full Text] [Related]

  • 17. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India.
    Ambroise M, Ghosh M, Mallikarjuna VS, Kurian A.
    Asian Pac J Cancer Prev; 2011 Mar 01; 12(3):625-9. PubMed ID: 21627355
    [Abstract] [Full Text] [Related]

  • 18. Elevated Interleukin-13 Receptor Alpha 1 Expression in Tumor Cells Is Associated with Poor Prognosis in Patients with Invasive Breast Cancer.
    Park MH, Kwon HJ, Kim JR, Lee B, Lee SJ, Bae YK.
    Ann Surg Oncol; 2017 Nov 01; 24(12):3780-3787. PubMed ID: 28634667
    [Abstract] [Full Text] [Related]

  • 19. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.
    Laurberg T, Alsner J, Tramm T, Jensen V, Lyngholm CD, Christiansen PM, Overgaard J.
    Acta Oncol; 2017 Jan 01; 56(1):59-67. PubMed ID: 27846764
    [Abstract] [Full Text] [Related]

  • 20. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH.
    Zhonghua Zhong Liu Za Zhi; 2010 Jul 01; 32(7):520-5. PubMed ID: 21029696
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 20.